----

| Delaware                                                       |   | 85-2789517                           |
|----------------------------------------------------------------|--------|--------------------------------------|
| (State or Other Jurisdiction of Incorporation or Organization) |   | (I.R.S. Employer Identification No.) |
| 628 Middlefield RoadPalo Alto, CA                              |   | 94301                                |
| (Address of Principal Executive Offices)                       |   | Zip Code                             |
| Title of Each Class                               | Trading Symbol(s) | Name of Each Exchange on Which Registered |
|---------------------------------------------------|-------------------|-------------------------------------------|
| Shares of Class A common stock, par value $0.0001 | JYAC              | The Nasdaq Stock Market LLC               |
| Large accelerated filer | ☐ |   | Accelerated filer         | ☐ |
|-------------------------|---------|--------|---------------------------|---------|
| Non-accelerated filer   | ☒ |   | Smaller reporting company | ☒ |
|                    |    |   | Emerging growth company   | ☒ |

----

----

----

|  | • | Part I – Item 1A. Risk Factors. |
|--|---------|--------------------------------------------|
|  | • | Part II – Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------|
|  | • | Part II – Item 8. Financial Statements and Supplementary Data. |
|--|---------|---------------------------------------------------------------------------|
|  | • | Part II – Item 9A. Controls and Procedures. |
|--|---------|--------------------------------------------------------|
|  | • | Part IV – Item 15. Exhibits, Financial Statement Schedules. |
|--|---------|------------------------------------------------------------------------|

----

|                                                                         | Page                                                                                                                       |
|------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
|                                                                         |                                                                                                                       |
| CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY | iii                                                                                                                        |
| PART I                                                                       | 1                                                                                                                          |
|                                                                         | Item 1. Business                                                                                                           | 1 |
|                                                                         | Item 1A. Risk Factors                                                                                                      | 17 |
|                                                                         | Item 1B. Unresolved Staff Comments                                                                                         | 45 |
|                                                                         | Item 2. Properties                                                                                                         | 45 |
|                                                                         | Item 3. Legal Proceedings                                                                                                  | 45 |
|                                                                         | Item 4. Mine Safety Disclosures                                                                                            | 45 |
| PART II                                                                      | 46                                                                                                                         |
|                                                                         | Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities | 46 |
|                                                                         | Item 6. Selected Financial Data                                                                                            | 47 |
|                                                                         | Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.                       | 48 |
|                                                                         | Item 7A. Quantitative and Qualitative Disclosures about Market Risk                                                        | 50 |
|                                                                         | Item 8. Financial Statements and Supplementary Data                                                                        | 50 |
|                                                                         | Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure                               | 50 |
|                                                                         | Item 9A. Controls and Procedures.                                                                                          | 50 |
|                                                                         | Item 9B. Other Information.                                                                                                | 51 |
| PART III                                                                     | 52                                                                                                                         |
|                                                                         | Item 10. Directors, Executive Officers and Corporate Governance                                                            | 52 |
|                                                                         | Item 11. Executive Compensation.                                                                                           | 61 |
|                                                                         | Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters                    | 62 |
|                                                                         | Item 13. Certain Relationships and Related Transactions, and Director Independence                                         | 64 |
|                                                                         | Item 14. Principal Accounting Fees and Services                                                                            | 66 |
| PART IV                                                                      | 68                                                                                                                         |
|                                                                         | Item 15. Exhibits, Financial Statement Schedules                                                                           | 68 |
|                                                                         | Item 16. Form 10-K Summary                                                                                                 | 69 |
| INDEX TO FINANCIAL STATEMENTS                                                | F-1                                                                                                                        |

----

----

Table of Contents

|  | • | “we,” “us,” “our,” “company” or “our company” are to Jiya Acquisition Corp., a Delaware corporation; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “common stock” are to our Class A common stock and our Class B common stock; |
|--|---------|------------------------------------------------------------------------------------------|
|  | • | “DGCL” refers to the Delaware General Corporation Law as the same may be amended from time to time; |
|--|---------|-----------------------------------------------------------------------------------------------------------------|
|  | • | “directors” are to our directors and director nominees; |
|--|---------|---------------------------------------------------------------------|
|  | • | “forward purchase agreement” are to an agreement that provides for the sale of the forward purchase shares to Samsara BioCapital and its permitted transferees in a private placement              that may close simultaneously with the closing of our initial business combination; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “forward purchase shares” are to the shares of our Class A common stock to be issued pursuant to the forward purchase agreement; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “forward transferees” are to any entity to which Samsara BioCapital transfers any portion of its obligation to purchase the forward purchase shares under the forward purchase agreement; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “founder shares” are to shares of Class B common stock initially purchased by our sponsor in a private placement prior to our initial public offering and the shares of Class A common              stock that will be issued upon the automatic conversion of the shares of Class B common stock at the time of our initial business combination as described herein; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “initial stockholders” are to holders of our founder shares prior to our initial public offering; |
|--|---------|---------------------------------------------------------------------------------------------------------------|
|  | • | “management” or our “management team” are to our executive officers and directors; |
|--|---------|------------------------------------------------------------------------------------------------------------|
|  | • | “public shares” are to shares of Class A common stock sold as part of the shares in our initial public offering (whether they were purchased in our initial public offering or thereafter              in the open market); |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “public stockholders” are to the holders of our public shares, including our initial stockholders and management team to the extent our initial stockholders and/or members of our              management team purchase public shares, provided that each initial stockholder’s and member of our management team’s status as a “public stockholder” will only exist with respect to such public shares; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “private placement shares” are to the shares issued to our sponsor in a private placement simultaneously with the closing of our initial public offering; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “Samsara BioCapital” or “Samsara” are to Samsara BioCapital, L.P., a Delaware limited partnership and its affiliates; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | “Samsara Fund” are to a domestic private pooled investment vehicle managed by Samsara BioCapital; and |
|--|---------|-------------------------------------------------------------------------------------------------------------------|
|  | • | “sponsor” are to Jiya Holding Company LLC, a Delaware limited liability company. |
|--|---------|----------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | our ability to select an appropriate target business or businesses; |
|--|---------|---------------------------------------------------------------------|
|  | • | our ability to complete our initial business combination; |
|--|---------|-----------------------------------------------------------|
|  | • | our expectations around the performance of the prospective target business or businesses; |
|--|---------|-------------------------------------------------------------------------------------------|
|  | • | our success in retaining or recruiting, or changes required in, our officers, key employees or directors following our initial business combination; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our officers and directors allocating their time to other businesses and potentially having conflicts of interest with our business or in approving our initial business combination; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our potential ability to obtain additional financing to complete our initial business combination; |
|--|---------|----------------------------------------------------------------------------------------------------|
|  | • | our pool of prospective target businesses; |
|--|---------|--------------------------------------------|
|  | • | the ability of our officers and directors to generate a number of potential business combination opportunities; |
|--|---------|-----------------------------------------------------------------------------------------------------------------|
|  | • | our public securities’ liquidity and trading; |
|--|---------|-----------------------------------------------------|
|  | • | the use of proceeds not held in the trust account or available to us from interest income on the trust account balance; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------|
|  | • | the trust account not being subject to claims of third parties; |
|--|---------|-----------------------------------------------------------------|
|  | • | our financial performance following our initial public offering; or |
|--|---------|---------------------------------------------------------------------|
|  | • | the other risks and uncertainties discussed in “Risk Factors” and elsewhere in this Annual Report. |
|--|---------|----------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 1. | Business |
|---------|----------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | Target significant unmet medical needs. We seek to identify businesses targeting significant unmet medical needs. We believe that filling              material gaps in treatment paradigms aligns all relevant stakeholders including patients, payors, and regulators and offers the best opportunity for differentiated risk-adjusted returns |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Have a high probability of clinical and regulatory success. The core of our investment approach is to target clinical stage assets that we              believe will have a high probability of technical and regulatory success. We believe that probability of technical success is directly correlated with deep understanding of the underlying pathobiology of a specific disease, the natural              history of the disease, current standard of care, and the regulatory landscape |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Leverage innovative science and approaches to drug development. We intend to identify businesses that leverage innovative approaches to drug              discovery and development including genetics, genomics, and biomarkers which we believe allow for early evidence of clinical benefit and more capital-efficient drug development with higher probabilities of success |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Possess scarcity value via a unique approach to disease targeting. We intend to identify businesses with unique therapeutic strategies to disease              targeting resulting in asset scarcity value and the creation of a differentiated profile for a publicly traded company |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Have a clear plan for capital formation. We believe that capital adequacy is key to success in drug development, and we will focus on businesses              that can be capitalized through key value inflection points |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Have strong existing Management or key expertise that can benefit from the managerial experience of our team and Board. We intend to focus on              companies with strong and experienced management teams who could benefit from the guidance of our management team and Board. In addition, if needed, members of our team or Board may be willing to take operating or board roles following a              business combination |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | subject us to negative economic, competitive and regulatory developments, any or all of which may have a substantial adverse impact on the particular industry in which we operate after              our initial business combination, and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | cause us to depend on the marketing and sale of a single product or limited number of products or services. |
|--|---------|-------------------------------------------------------------------------------------------------------------|
| Type of Transaction                                                 | WhetherStockholderApproval isRequired  |
|---------------------------------------------------------------------|---------------------------------------------|
| Purchase of assets                                                  | No                                          |
| Purchase of stock of target not involving a merger with the company | No                                          |
| Merger of target into a subsidiary of the company                   | No                                          |
| Merger of the company with a target                                 | Yes                                         |

----

Table of Contents

|  | • | We issue shares of common stock that will be equal to or in excess of 20% of the number of our shares of common stock then outstanding (other than in a public offering); |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Any of our directors, officers or substantial stockholders (as defined by Nasdaq rules) has a 5% or greater interest (or such persons collectively have a 10% or greater interest),              directly or indirectly, in the target business or assets to be acquired or otherwise and the present or potential issuance of common stock could result in an increase in outstanding common stock or voting power of 5% or more; or |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | The issuance or potential issuance of common stock will result in our undergoing a change of control. |
|--|---------|-------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | conduct the redemptions in conjunction with a proxy solicitation pursuant to Regulation 14A of the Exchange Act, which regulates the solicitation of proxies, and not pursuant to the              tender offer rules, and |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | file proxy materials with the SEC. |
|--|---------|------------------------------------|
|  | • | conduct the redemptions pursuant to Rule 13e-4 and Regulation 14E of the Exchange Act, which regulate issuer tender offers, and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | file tender offer documents with the SEC prior to completing our initial business combination, which contain substantially the same financial and other information about the initial              business combination and the redemption rights as is required under Regulation 14A of the Exchange Act, which regulates the solicitation of proxies. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item 1A. | Risk Factors |
|----------|--------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | restrictions on the nature of our investments; and |
|--|---------|----------------------------------------------------|
|  | • | restrictions on the issuance of securities, |
|--|---------|---------------------------------------------|
|  | • | registration as an investment company with the SEC; |
|--|---------|-----------------------------------------------------|

----

Table of Contents

|  | • | adoption of a specific form of corporate structure; and |
|--|---------|---------------------------------------------------------|
|  | • | reporting, record keeping, voting, proxy and disclosure requirements and other rules and regulations that we are not subject to. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | we have a board that includes a majority of ‘independent directors,’ as defined under the rules of Nasdaq; |
|--|---------|------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | we have a compensation committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities; and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | we have a nominating committee of our board that is comprised entirely of independent directors with a written charter addressing the committee’s purpose and responsibilities. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | may significantly dilute the equity interest of investors in this offering; |
|--|---------|-----------------------------------------------------------------------------|
|  | • | may subordinate the rights of holders of Class A common stock if shares of preferred stock are issued with rights senior to those afforded our Class A common stock; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | could cause a change in control if a substantial number of shares of Class A common stock is issued, which may affect, among other things, our ability to use our net operating loss              carry forwards, if any, and could result in the resignation or removal of our present officers and directors; and |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | may adversely affect prevailing market prices for our shares, Class A common stock. |
|--|---------|-------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | solely dependent upon the performance of a single business, property or asset, or |
|--|---------|-----------------------------------------------------------------------------------|
|  | • | dependent upon the development or market acceptance of a single or limited number of products, processes or services. |
|--|---------|-----------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | a limited availability of market quotations for our securities; |
|--|---------|-----------------------------------------------------------------|
|  | • | reduced liquidity for our securities; |
|--|---------|---------------------------------------|
|  | • | a determination that our Class A common stock is a “penny stock” which will require brokers trading in our Class A common stock to adhere to more stringent rules and possibly result in              a reduced level of trading activity in the secondary trading market for our securities; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | a limited amount of news and analyst coverage; and |
|--|---------|----------------------------------------------------|
|  | • | a decreased ability to issue additional securities or obtain additional financing in the future. |
|--|---------|--------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | default and foreclosure on our assets if our operating revenues after an initial business combination are insufficient to repay our debt obligations; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | acceleration of our obligations to repay the indebtedness even if we make all principal and interest payments when due if we breach certain covenants that require the maintenance of              certain financial ratios or reserves without a waiver or renegotiation of that covenant; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our immediate payment of all principal and accrued interest, if any, if the debt is payable on demand; |
|--|---------|--------------------------------------------------------------------------------------------------------|
|  | • | our inability to obtain necessary additional financing if the debt contains covenants restricting our ability to obtain such financing while the debt is outstanding; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | our inability to pay dividends on our Class A common stock; |
|--|---------|-------------------------------------------------------------|
|  | • | using a substantial portion of our cash flow to pay principal and interest on our debt, which will reduce the funds available for dividends on our Class A common stock if declared,              expenses, capital expenditures, acquisitions and other general corporate purposes; |
|--|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | limitations on our flexibility in planning for and reacting to changes in our business and in the industry in which we operate; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------|
|  | • | increased vulnerability to adverse changes in general economic, industry and competitive conditions and adverse changes in government regulation; and |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | limitations on our ability to borrow additional amounts for expenses, capital expenditures, acquisitions, debt service requirements, execution of our strategy and other purposes and              other disadvantages compared to our competitors who have less debt. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

|  | • | costs and difficulties inherent in managing cross-border business operations; |
|--|---------|-------------------------------------------------------------------------------|
|  | • | rules and regulations regarding currency redemption; |
|--|---------|------------------------------------------------------|
|  | • | complex corporate withholding taxes on individuals; |
|--|---------|-----------------------------------------------------|
|  | • | laws governing the manner in which future business combinations may be effected; |
|--|---------|----------------------------------------------------------------------------------|
|  | • | exchange listing and/or delisting requirements; |
|--|---------|-------------------------------------------------|
|  | • | tariffs and trade barriers; |
|--|---------|-----------------------------|
|  | • | regulations related to customs and import/export matters; |
|--|---------|-----------------------------------------------------------|
|  | • | local or regional economic policies and market conditions; |
|--|---------|------------------------------------------------------------|
|  | • | unexpected changes in regulatory requirements; |
|--|---------|------------------------------------------------|
|  | • | challenges in managing and staffing international operations; |
|--|---------|---------------------------------------------------------------|
|  | • | longer payment cycles; |
|--|---------|------------------------|
|  | • | tax issues, such as tax law changes and variations in tax laws as compared to the United States; |
|--|---------|--------------------------------------------------------------------------------------------------|
|  | • | currency fluctuations and exchange controls; |
|--|---------|----------------------------------------------|
|  | • | rates of inflation; |
|--|---------|---------------------|
|  | • | challenges in collecting accounts receivable; |
|--|---------|-----------------------------------------------|
|  | • | cultural and language differences; |
|--|---------|------------------------------------|
|  | • | employment regulations; |
|--|---------|-------------------------|
|  | • | underdeveloped or unpredictable legal or regulatory systems; |
|--|---------|--------------------------------------------------------------|

----

Table of Contents

|  | • | corruption; |
|--|---------|-------------|
|  | • | protection of intellectual property; |
|--|---------|--------------------------------------|
|  | • | social unrest, crime, strikes, riots and civil disturbances; |
|--|---------|--------------------------------------------------------------|
|  | • | regime changes and political upheaval; |
|--|---------|----------------------------------------|
|  | • | terrorist attacks and wars; and |
|--|---------|---------------------------------|
|  | • | deterioration of political relations with the United States. |
|--|---------|--------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Item 1B. | Unresolved Staff Comments |
|----------|---------------------------|
| Item 2. | Properties |
|---------|------------|
| Item 3. | Legal Proceedings |
|---------|-------------------|
| Item 4. | Mine Safety Disclosures |
|---------|-------------------------|

----

Table of Contents

| Item 5. | Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities |
|---------|--------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Item 6. | Selected Financial Data |
|---------|-------------------------|

----

Table of Contents

| Item 7. | Management’s Discussion and Analysis of Financial Condition and Results of Operations. |
|---------|----------------------------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| Item 7A. | Quantitative and Qualitative Disclosures about Market Risk |
|----------|------------------------------------------------------------|

| Item 8. | Financial Statements and Supplementary Data |
|---------|---------------------------------------------|

| Item 9. | Changes in and Disagreements with Accountants on Accounting and Financial Disclosure |
|---------|--------------------------------------------------------------------------------------|

| Item 9A. | Controls and Procedures. |
|----------|--------------------------|

----

Table of Contents

| Item 9B. | Other Information. |
|----------|--------------------|

----

Table of Contents

| Item 10. | Directors, Executive Officers and Corporate Governance |
|----------|--------------------------------------------------------|

| Name                           | Age | Position                                   |
|--------------------------------|-----|-------------------------------------------------|
| Srinivas Akkaraju, M.D., Ph.D. | 53  | Chairman                                        |
| Rekha Hemrajani                | 51  | Director and Chief Executive Officer            |
| Richard Van Doren              | 44  | Director, Secretary and Chief Financial Officer |
| Cory Freedland, Ph.D.          | 45  | Director and Chief Investment Officer           |
| Perry Karsen                   | 65  | Director                                        |
| Dr. Pamela Klein               | 58  | Director                                        |
| Daniel Spiegelman              | 62  | Director                                        |
| Dr. Steve Kelsey               | 60  | Director                                        |
| Mayank Gandhi, M.D.            | 43  | Vice President, Corporate Development           |

----

Table of Contents

----

Table of Contents

----

Table of Contents

|  | • | assisting board oversight of (1) the integrity of our financial statements, (2) our compliance with legal and regulatory requirements, (3) our independent auditor’s qualifications and                  independence, and (4) the performance of our internal audit function and independent auditors; the appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent                  registered public accounting firm engaged by us; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | pre-approving all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged by us, and establishing pre-approval                  policies and procedures; reviewing and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence; |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | setting clear policies for audit partner rotation in compliance with applicable laws and regulations; obtaining and reviewing a report, at least annually, from the independent                  auditors describing (1) the independent auditor’s internal quality-control procedures and (2) any material issues raised by the most recent internal quality-control review, or peer review, of the audit firm, or by any inquiry or                  investigation by governmental or professional authorities, within the preceding five years respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | meeting to review and discuss our annual audited financial statements and quarterly financial statements with management and the independent auditor, including reviewing our specific                  disclosures under “Management’s Discussion and Analysis of Financial Condition and Results of Operations”; reviewing and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated                  by the SEC prior to us entering into such transaction; and |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | reviewing with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including any correspondence with regulators                  or government agencies and any employee complaints or published reports that raise material issues regarding our financial statements or accounting policies and any significant changes in accounting standards or rules promulgated by the                  Financial Accounting Standards Board, the SEC or other regulatory authorities. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and approving on an annual basis the corporate goals and objectives relevant to our chief executive officer’s compensation, evaluating our chief executive officer’s                  performance in light of such goals and objectives and determining and approving the remuneration (if any) of our chief executive officer’s based on such evaluation; |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing and approving the compensation of all of our other Section 16 executive officers; |
|--|---------|---------------------------------------------------------------------------------------------|
|  | • | reviewing our executive compensation policies and plans; |
|--|---------|----------------------------------------------------------|
|  | • | implementing and administering our incentive compensation equity-based remuneration plans; |
|--|---------|--------------------------------------------------------------------------------------------|
|  | • | assisting management in complying with our proxy statement and annual report disclosure requirements; |
|--|---------|-------------------------------------------------------------------------------------------------------|
|  | • | approving all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers and employees; |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | producing a report on executive compensation to be included in our annual proxy statement; and |
|--|---------|------------------------------------------------------------------------------------------------|
|  | • | reviewing, evaluating and recommending changes, if appropriate, to the remuneration for directors. |
|--|---------|----------------------------------------------------------------------------------------------------|
|  | • | identifying, screening and reviewing individuals qualified to serve as directors, consistent with criteria approved by the board, and recommending to the board of directors candidates                  for nomination for appointment at the annual general meeting or to fill vacancies on the board of directors; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | developing and recommending to the board of directors and overseeing implementation of our corporate governance guidelines; |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------|
|  | • | coordinating and overseeing the annual self-evaluation of the board of directors, its committees, individual directors and management in the governance of the company; and |
|--|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | reviewing on a regular basis our overall corporate governance and recommending improvements as and when necessary. |
|--|---------|--------------------------------------------------------------------------------------------------------------------|
|  | • | the corporation could financially undertake the opportunity; |
|--|---------|--------------------------------------------------------------|
|  | • | the opportunity is within the corporation’s line of business; and |
|--|---------|-------------------------------------------------------------------------|
|  | • | it would not be fair to our company and its stockholders for the opportunity not to be brought to the attention of the corporation. |
|--|---------|-------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| Individual                     | Entity                                                         | Entity’s Business                                                                                                                                                                                                             | Affiliation                    |
|--------------------------------|----------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------|
| Srinivas Akkaraju, M.D., Ph.D. | Samsara BioCapital, LLC                                        | Investment Adviser                                                                                                                                                                                                                  | Managing Member                |
|                           | Samsara BioCapital GP, LLC                                     | Investment Adviser                                                                                                                                                                                                                  | Managing Member                |
|                           | A2 Biotherapeutics, Inc.                                       | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | Autobahn Labs, Inc.                                            | Biotech incubator                                                                                                                                                                                                                   | Director                       |
|                           | Chinook Therapeutics, Inc. (NASD:  KDNY)                  | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | Codex Health, Inc.                                             | Digital Health                                                                                                                                                                                                                      | Chairman of the Board          |
|                           | Dewpoint Therapeutics, Inc.                                    | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | Intercept Pharmaceutical, Inc. (NASD:  ICPT)              | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | MiroBio, Ltd                                                   | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | Synthekine, Inc.                                               | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | Syros Pharmaceuticals, Inc. (NASD:  SYRS)                 | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | Tentarix Biotherapeutics, Inc.                                 | Biopharma                                                                                                                                                                                                                           | Director                       |
|                           | Theia Therapeutics, Inc.                                       | Biopharma                                                                                                                                                                                                                           | Director                       |
| Rekha Hemrajani                | Adverum Biotechnologies (NASD: ADVM)                           | Adverum is a clinical-stage gene therapy company targeting unmet medical need in ocular and rare diseases.                                                                                                                          | Director                       |
|                           | ALX Oncology (NASD: ALXO)                                      | ALX Oncology is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway                  and bridge the innate and adaptive immune system. | Director                       |
|                           | Hemmo Pharma Pvt Ltd & Hemmo Pharma LLP (related entities) | Private company based in India - supplier & manufacturer of synthetic peptide APIs                                                                                                                                              | Director, Shareholder, Partner |
| Cory Freedland, Ph.D.          | Neurogene, Inc.                                                | Preclinical gene therapy company targeting neurological diseases                                                                                                                                                                    | Board Member                   |
|                           | Nura Bio, Inc.                                                 | Preclinical company targeting neurodegeneration                                                                                                                                                                                     | Board Member                   |

----

Table of Contents

|              | Palvella Therapeutics              | Clinical stage company developing novel therapies for rare dermatological diseases | Board Member             |
|-------------------|------------------------------------|------------------------------------------------------------------------------------|--------------------------|
|              | Nalo Therapeutics                  | Preclinical oncology company                                                       | Board Member             |
|              | Tentarix Biotherapeutics           | Start-up targeting novel multi-domain protein therapeutics                         | Board Member             |
|              | Omniox, Inc.                       | Developing novel therapies for diseases characterized by hypoxia                   | Board Member             |
| Richard Van Doren | Samsara BioCapital, LLC            | Investment Adviser                                                                 | Chief Financial Officer  |
|              | Nalo Therapeutics, Inc.            | Biopharma                                                                          | Chief Financial Officer  |
|              | Autobahn Labs, Inc.                | Biotech incubator                                                                  | Chief Financial Officer  |
|              | Theia Therapeutics, Inc.           | Biopharma                                                                          | Chief Financial Officer  |
| Perry Karsen      | Samsara BioCapital                 | Investment firm                                                                    | Venture partner          |
|              | Autobahn Labs                      | Biotech incubator                                                                  | Executive Chair of Board |
|              | Jounce Therapeutics (NASD: JNCE)   | Biopharma                                                                          | Chairman of Board        |
|              | Nitrome Biosciences                | Biopharma                                                                          | Executive Chair of Board |
|              | Intellia Therapeutics (NASD: NTLA) | Gene editing therapeutics                                                          | Independent Director     |
|              | ESCAPE Bio                         | Biopharma                                                                          | Independent Director     |
|              | Graphite Bio                       | Biopharma                                                                          | Independent Director     |
| Dr. Pamela Klein  | Olema Oncology                     | Biopharma                                                                          | Chief Medical Officer    |
|              | Argenx                             | Biopharma                                                                          | Independent Director     |
|              | Springbank Pharma                  | Biopharma                                                                          | Independent Director     |
|              | Patrys                             | Biopharma                                                                          | Independent Director     |
|              | I-Mab Biopharma                    | Biopharma                                                                          | Independent Director     |
| Daniel Spiegelman | Tizona Therapeutics                | Biopharma                                                                          | Independent Director     |
|              | Myriad Genetics                    | Biopharma                                                                          | Independent Director     |
|              | Spruce Biosciences                 | Biopharma                                                                          | Independent Director     |
|              | Opthea Ltd                         | Biopharma                                                                          | Independent Director     |
|             | Recardia             | Biopharma        | Independent Director |
|------------------|----------------------|------------------|----------------------|
| Dr. Steve Kelsey | Revolution Medicines | Biotechnology Co | President            |

----

Table of Contents

|  | • | Our executive officers and directors are not required to, and will not, commit their full time to our affairs, which may result in a conflict of interest in allocating their time                  between our operations and our search for a business combination and their other businesses. Each of our executive officers is engaged in several other business endeavors for which he may be entitled to substantial compensation, and our                  executive officers are not obligated to contribute any specific number of hours per week to our affairs. |
|--|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | • | Our initial stockholders purchased founder shares prior to the date of this Annual Report and purchased private placement shares in a transaction that closed simultaneously with the                  closing of our initial public offering. Our initial stockholders have entered into agreements with us, pursuant to which they have agreed to waive their redemption rights with respect to their founder shares, private placement shares and                  any public shares they hold in connection with the completion of our initial business combination. The other members of our management team have entered into agreements similar to the one entered into by our initial stockholders with                  respect to any public shares acquired by them in or after our initial public offering. Additionally, our initial stockholders have agreed to waive their rights to liquidating distributions from the trust account with respect to their                  founder shares if we fail to complete our initial business combination within the prescribed time frame. Furthermore, our initial stockholders have agreed not to transfer, assign or sell any of their founder shares until the earlier to                  occur of: (i) one year after the completion of our initial business combination and (ii) the date following the completion of our initial business combination on which we complete a liquidation, merger, capital stock exchange or other                  similar transaction that results in all of our stockholders having the right to exchange their common stock for cash, securities or other property. Notwithstanding the foregoing, if the closing price of our Class A common stock equals or                  exceeds $12.00 per share (as adjusted for stock splits, stock capitalizations, reorganizations, recapitalizations and the like) for any 20 trading days within any 30-trading day period commencing at least 120 days after our initial                  business combination, the founder shares will be released from the lockup. Because each of our executive officers and director nominees will own common stock directly or indirectly, they may have a conflict of interest in determining                  whether a particular target business is an appropriate business with which to effectuate our initial business combination. |
|--|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | Our officers and directors may have a conflict of interest with respect to evaluating a particular business combination if the retention or resignation of any such officers and                  directors was included by a target business as a condition to any agreement with respect to our initial business combination. |
|--|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Item 11. | Executive Officer and Director Compensation. |
|----------|----------------------------------------------|

----

Table of Contents

| Item 12. | Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters |
|----------|------------------------------------------------------------------------------------------------|

----

Table of Contents

|  | • | each person known by us to be the beneficial owner of more than 5% of our outstanding shares of common stock; |
|--|---------|---------------------------------------------------------------------------------------------------------------|
|  | • | each of our executive officers and directors; and |
|--|---------|---------------------------------------------------|
|  | • | all our executive officers and directors as a group. |
|--|---------|------------------------------------------------------|
|                                                                   |   | Class A Common Stock              |      |   | Class B Common Stock(2)       |   |
|------------------------------------------------------------------------|--------|-----------------------------------|-----------|--------|-------------------------------|--------|
| Name and Address of Beneficial Owner(1)                                |   | Number ofSharesBeneficially Owned |      |   | ApproximatePercentage ofClass |   |   | Number ofSharesBeneficiallyOwned |   |   | ApproximatePercentage ofClass |   |
| Glazer Capital, LLC(3)                                                 |   |                              | 1,037,830 |   |                          |   | 9.6 | % |   |   | — |   |   |   | — |   |
| Citadel(4)                                                             |   |                              | 770,357   |   |                          |   | 7.1 | % |   |   | — |   |   |   | — |   |
| Acuta Capital Partners, LLC(5)                                         |   |                              | 562,500   |   |                          |   | 5.2 | % |   |   | — |   |   |   | — |   |
| Aristeia Capital, L.L.C. (6)                                           |   |                              | 526,467   |   |                          |   | 4.8 | % |   |   | — |   |   |   | — |   |
| Jiya Holding Company LLC(7)                                            |   |                              | 507,041   |   |                          |   | 4.7 | % |   |   | 2,130,000 |   |   |   | 82.3 | % |
| Srinivas Akkaraju, M.D., Ph.D. (7)                                     |   |                              | 507,041   |   |                          |   | 4.7 | % |   |   | 2,160,000 |   |   |   | 83.5 | % |
| Rekha Hemrajani                                                        |   |                              | —   |   |                          |   | — |   |   |   | 200,000 |   |   |   | 7.7 | % |
| Richard Van Doren                                                      |   |                              | —   |   |                          |   | — |   |   |   | 30,000 |   |   |   | 1.2 | % |
| Cory Freedland, Ph.D.                                                  |   |                              | —   |   |                          |   | — |   |   |   | 30,000 |   |   |   | 1.2 | % |
| Perry Karsen                                                           |   |                              | —   |   |                          |   | — |   |   |   | 30,000 |   |   |   | 1.2 | % |
| Dr. Pamela Klein                                                       |   |                              | —   |   |                          |   | — |   |   |   | 30,000 |   |   |   | 1.2 | % |
| Daniel Spiegelman                                                      |   |                              | —   |   |                          |   | — |   |   |   | 30,000 |   |   |   | 1.2 | % |
| Dr. Steve Kelsey                                                       |   |                              | —   |   |                          |   | — |   |   |   | 30,000 |   |   |   | 1.2 | % |
| Mayank Gandhi, M.D.                                                    |   |                              | —   |   |                          |   | — |   |   |   | 48,000 |   |   |   | 1.9 | % |
|  All executive officers and directors as a group, (8 individuals) |   |                              | 507,041   |   |                          |   | 4.7 | % |   |   | 2,588,010 |   |   |   | 98.1 | % |
| * | Less than one percent. |
|---|------------------------|
| (1) | Unless otherwise noted, the business address of each of the following is 628 Middlefield Road, Palo Alto, CA 94301. |
|-----|---------------------------------------------------------------------------------------------------------------------|
| (2) | Interests shown consist solely of founder shares, classified as Class B common stock. Such shares will automatically convert into Class A common stock concurrently with or immediately                  following the consummation of our initial business combination on a one-for-one basis, subject to adjustment. Excludes forward purchase shares that will only be issued, if at all, at the time of our initial business combination. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (3) | The information in the table above is based solely on information contained in this stockholder’s Schedule 13G under the Exchange Act filed by such stockholder with the SEC. Includes                  shares of Class A common stock held by certain funds and managed accounts to which Glazer Capital, LLC serves as investment manager. Mr. Paul J. Glazer, serves as the Managing Member of Glazer Capital. The address of Glazer Capital, LLC                  is 250 West 55th Street, Suite 30A, New York, New York 10019. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (4) | The information in the table above is based solely on information contained in this stockholder’s Schedule 13G under the Exchange Act filed by such stockholder with the SEC. Includes                  shares held by Citadel Equity Fund Ltd. (“CEFL”), Citadel Multi-Strategy Equities Master Fund Ltd. (“CM”) and Citadel Securities LLC (“Citadel Securities”). Citadel Advisors LLC (“Citadel Advisors”) is the portfolio manager for CEFL and                  CM. Citadel Advisors Holdings LP (“CAH”) is the sole member of Citadel Advisors. Citadel GP LLC (“CGP”) is the general partner of CAH. CALC IV LP (“CALC4”) is the non-member manager of Citadel Securities. Citadel Securities GP LLC                  (“CSGP”) is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP. Includes 770,300 shares that may be deemed to be beneficially owned by Citadel                  Advisors, CAH and CGP, and 57 shares that may be deemed to be beneficially owned by CALC4 and CSGP. Kenneth Griffin may be deemed to beneficially own 770,357 shares of Class A common stock. The address of Citadel is 628 Middlefield Road,                  Palo Alto, California 94301. |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (5) | The information in the table above is based solely on information contained in this stockholder’s Schedule 13G under the Exchange Act filed by such stockholder with the SEC. The funds                  managed by Acuta Capital Partners LLC (“Acuta”) hold Class A common stock for the benefit of their investors and have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Class A                  common stock. Acuta is the general partner and investment adviser of investment funds. Dr. Anupam Dalal is the control person of Acuta. Acuta and Dr. Anupam Dalal each disclaims beneficial ownership of the Class A common stock except to                  the extent of their pecuniary interest therein. The address of Acuta is 1301 Shoreway Road, Suite 350, Belmont, CA 94002. |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

Table of Contents

| (6) | The information in the table above is based solely on information contained in this stockholder’s Schedule 13G under the Exchange Act filed by such stockholder with the SEC. Aristeia                  Capital, L.L.C. is the investment manager of, and has voting and investment control with respect to the securities described above held by, one or more private investment funds. The address of Aristeia Capital is One Greenwich Plaza, 3rd                  Floor, Greenwich, CT 06830. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| (7) | Jiya Holding Company LLC is wholly owned by Samsara BioCapital, L.P. Dr. Srinivas Akkaraju, M.D., Ph.D, has voting and dispositive control over these shares via his control of Samsara                  BioCapital, L.P.’s general partner, Samsara BioCapital GP, LLC. Dr. Akkaraju disclaims beneficial ownership of these shares except to the extent of any pecuniary interest in such shares. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| Item 13. | Certain Relationships and Related Transactions, and Director Independence |
|----------|---------------------------------------------------------------------------|

----

Table of Contents

----

Table of Contents

| Item 14. | Principal Accounting Fees and Services |
|----------|----------------------------------------|

----

Table of Contents

----

Table of Contents

| Item 15. | Exhibits, Financial Statement Schedules |
|----------|-----------------------------------------|

|                                                    | Page |
|---------------------------------------------------------|------|
| Report of Independent Registered Public Accounting Firm | F-2  |
| Balance Sheet                                           | F-3  |
| Statement of Operations                                 | F-4  |
| Statement of Changes in Stockholders’ Equity      | F-5  |
| Statement of Cash Flows                                 | F-6  |
| Notes to Financial Statements                           | F-7  |
| ExhibitNo. | Description                                                                                                                                                                                                                                                                              |
|------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 3.1        | First Amended and Restated Certificate of Incorporation (incorporated herein by reference to Exhibit 3.1 to the Current Report on Form 8-K                  dated November 20, 2020)                                                                                                     |
| 3.2        | Amended and Restated Bylaws (incorporated herein by reference to Exhibit 3.2 of the Company’s Registration Statement on Form S-1 (File No.                  333-249808) filed with the SEC on November 2, 2020).                                                                   |
| 4.1**      | Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934, As Amended                                                                                                                                                                           |
| 10.1       | Letter Agreement, dated November 18, 2020, among the Company and its officers, directors and Jiya Holding Company, LLC, dated November 18,                  2020 (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K dated November 20, 2020).                  |
| 10.2       | Investment Management Trust Agreement, dated November 18, 2020, between the Company and Continental Stock Transfer & Trust Company, as                  trustee (incorporated by reference to Exhibit 10.2 to the Current Report on Form 8-K dated November 20, 2020).               |
| 10.3       | Registration Rights Agreement, dated November 18, 2020, between the Company and certain security holders (incorporated by reference to Exhibit                  10.3 to the Current Report on Form 8-K dated November 20, 2020).                                                         |
| 10.4       | Private Placement Purchase Agreement, dated November 18, 2020, between the Company and Jiya Holding Company, LLC (incorporated by reference to                  Exhibit 10.4 to the Current Report on Form 8-K dated November 20, 2020).                                                 |
| 10.5       | Administrative Services Agreement, dated November 18, 2020, between the Company and Jiya Holding Company, LLC (incorporated by reference to                  Exhibit 10.5 to the Current Report on Form 8-K dated November 20, 2020).                                                    |
| 10.6       | Offer Letter between Jiya Acquisition Corp. and Rekha Hemrajani, dated October 30, 2020 (incorporated herein by reference to Exhibit 10.9 of                  the Company’s Registration Statement on Form S-1 (File No. 333-249808) filed with the SEC on November 2, 2020)       |
| 10.7**     | Offer Letter between Jiya Acquisition Corp. and Mayank Gandhi, dated November 5, 2020                                                                                                                                                                                                    |
| 31.1*      | Certification of the Registrant’s Chief Executive Officer (Principal Executive Officer) Pursuant to Rules 13a-14(a) and 15d-14(a) under the                  Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                |
| 31.2*      | Certification of the Registrant’s Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to Rules 13a-14(a) and                  15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. |
| 32.1*      | Certification of the Registrant’s Chief Executive Officer (Principal Executive Officer) Pursuant to 18 U.S.C. Section 1350, as Adopted                  Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                 |
| 32.2*      | Certification of the Registrant’s Chief Financial Officer (Principal Financial and Accounting Officer) Pursuant to 18 U.S.C. Section 1350, as                  Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                  |

| * | Filed herewith. |
|---|-----------------|

| ** | Previously filed. |
|----|-------------------|

----

Table of Contents

| Item 16. | Form 10-K Summary |
|----------|-------------------|

----

Table of Contents

|   | Jiya Acquisition Corp. |
|--------|------------------------|
|   |                   |
|   | By:                    | /s/  Rekha Hemrajani |
|   | Name:                  | Rekha Hemrajani |
|   | Title:                 | Chief Executive Officer |
| Name                        |   | Positon                                                                       | Date              |
|-----------------------------|--------|-------------------------------------------------------------------------------|-------------------|
|                        |   |                                                                          |              |
| /s/ Srinivas Akkaruju       |   | Chairman                                                                      | February 18, 2022 |
| Srinivas Akkaruju           |   |                                                                          |              |
|                        |   |                                                                          |              |
| /s/  Rekha Hemrajani   |   | Chief Executive Officer and Director(Principal Executive Officer)             | February 18, 2022 |
| Rekha Hemrajani             |   |                                                                          |              |
|                        |   |                                                                          |              |
| /s/  Richard Van Doren |   | Chief Financial Officer, Secretary and Director(Principal Accounting Officer) | February 18, 2022 |
| Richard Van Doren           |   |                                                                          |              |
|                        |   |                                                                          |              |
| /s/ Cory Freedland          |   | Chief Investment Officer and Director                                         | February 18, 2022 |
| Cory Freedland              |   |                                                                          |              |
|                        |   |                                                                          |              |
| /s/ Perry Karsen            |   | Director                                                                      | February 18, 2022 |
| Perry Karsen                |   |                                                                          |              |
|                        |   |                                                                          |              |
| /s/ Dr. Pamela Klein        |   | Director                                                                      | February 18, 2022 |
| Dr. Pamela Klein            |   |                                                                          |              |
|                        |   |                                                                          |              |
| /s/ Daniel Spiegelman       |   | Director                                                                      | February 18, 2022 |
| Daniel Spiegelman           |   |                                                                          |              |
|                        |   |                                                                          |              |
| /s/ Dr. Steve Kelsey        |   | Director                                                                      | February 18, 2022 |
| Dr. Steve Kelsey            |   |                                                                          |              |

----

Table of Contents

| Report of Independent Registered Public Accounting Firm          | F-2         |
|------------------------------------------------------------------|-------------|
| Financial Statements:                                            |        |
| Balance Sheet (As Restated)                                      | F-3         |
| Statement of Operations (As Restated)                            | F-4         |
| Statement of Changes in Stockholders’ Equity (As Restated) | F-5         |
| Statement of Cash Flows (As Restated)                            | F-6         |
| Notes to Financial Statements                                    | F-7 to F-18 |

----

Table of Contents

----

Table of Contents

| ASSETS                                                                                                                                                                                      |   |   |        |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|--------|-------------|
| Current Assets                                                                                                                                                                              |   |   |        |
| Cash                                                                                                                                                                                        |   | $      | 1,889,565   |   |
| Prepaid expenses                                                                                                                                                                            |   |   | 521,067     |   |
| Total Current Assets                                                                                                                                                                        |   |   | 2,410,632   |   |
|                                                                                                                                                                                        |   |   |        |   |
| Cash and marketable securities held in Trust Account                                                                                                                                        |   |   | 103,522,529 |   |
| TOTAL ASSETS                                                                                                                                                                                |   | $      | 105,933,161 |   |
|                                                                                                                                                                                        |   |   |        |   |
| LIABILITIES AND STOCKHOLDERS’ DEFICIT                                                                                                                                                 |   |   |        |   |
| Current Liabilities                                                                                                                                                                         |   |   |        |   |
| Accrued expenses                                                                                                                                                                            |   | $      | 50,892      |   |
| Accrued offering costs                                                                                                                                                                      |   |   | 50,832      |   |
| Due to Sponsor                                                                                                                                                                              |   |   | 2,305       |   |
| Promissory note – related party                                                                                                                                                       |   |   | 348         |   |
| Total Current Liabilities                                                                                                                                                                   |   |   | 104,377     |   |
|                                                                                                                                                                                        |   |   |        |   |
| Deferred underwriting payable                                                                                                                                                               |   |   | 3,623,214   |   |
| Total Liabilities                                                                                                                                                                           |   |   | 3,727,591   |   |
|                                                                                                                                                                                        |   |   |        |   |
| Commitments and Contingencies                                                                                                                                                               |   |   |        |   |
|                                                                                                                                                                                        |   |   |        |   |
| Class A common stock subject to possible redemption 10,352,040 shares at redemption value                                                                                                   |   |   | 103,520,402 |   |
|                                                                                                                                                                                        |   |   |        |   |
| Stockholders’ Deficit                                                                                                                                                                 |   |   |        |   |
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; no shares issued and outstanding                                                                                           |   |   | —     |   |
| Class A common stock, $0.0001 par value; 100,000,000 shares authorized; 507,041 shares issued and outstanding (excluding 10,352,040 shares                  subject to possible redemption) |   |   | 51          |   |
| Class B common stock, $0.0001 par value; 10,000,000 shares authorized; 2,588,010 shares issued and outstanding                                                                              |   |   | 259         |   |
| Additional paid-in capital                                                                                                                                                                  |   |   | 22,500      |   |
| Accumulated deficit                                                                                                                                                                         |   |   | (1,337,642  | ) |
| Total Stockholders’ Deficit                                                                                                                                                           |   |   | (1,314,832  | ) |
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT                                                                                                                                           |   | $      | 105,933,161 |   |

----

Table of Contents

| Formation and operational costs                                             |   | $      | 244,346   |   |
|-----------------------------------------------------------------------------|--------|--------|-----------|--------|
| Stock-based compensation expense                                            |   |   | 22,500    |   |
| Loss from operations                                                        |   |   | (266,846  | )      |
|                                                                        |   |   |      |   |
| Other income:                                                               |   |   |      |   |
| Interest earned on marketable securities held in Trust Account              |   |   | 3,108     |   |
| Unrealized loss on marketable securities held in Trust Account              |   |   | (981      | )      |
| Other income, net                                                           |   |   | 2,127     |   |
|                                                                        |   |   |      |   |
| Loss before provision for income taxes                                      |   |   | (264,719  | )      |
| Net loss                                                                    |   | $      | (264,719  | )      |
|                                                                        |   |   |      |   |
| Basic and diluted weighted average shares outstanding, Class A Common stock |   |   | 3,398,183 |   |
|                                                                        |   |   |      |   |
| Basic and diluted net loss per share, Class A Common stock                  |   | $      | (0.04     | )      |
|                                                                        |   |   |      |   |
| Basic and diluted weighted average shares outstanding, Class B Common stock |   |   | 2,684,176 |   |
|                                                                        |   |   |      |   |
| Basic and diluted net loss per share, Class B Common stock                  |   | $      | (0.04     | )      |

----

Table of Contents

|                                                              |   | Class ACommon Stock |    |   | Class BCommon Stock |   |    | AdditionalPaid-in |   |   | Accumulated |   |   | TotalStockholders’ |    |
|-------------------------------------------------------------------|--------|---------------------|---------|--------|---------------------|--------|---------|-------------------|--------|--------|-------------|--------|--------|--------------------------|---------|
|                                                              |   | Shares              |    |   | Amount              |   |    | Shares            |   |   | Amount      |   |   | Capital                  |    |   | Deficit |   |   | Equity |   |
| Balance – August 27, 2020 (Inception)                       |   |                | — |   |                | $      | — |              |   |   | —     |   |   | $                        | — |   |   | $ | — |   |   | $ | — |   |   | $ | — |   |
|                                                              |   |                |    |   |                |   |    |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Issuance of Class B common stock                                  |   |                | — |   |                |   | — |              |   |   | 2,875,000   |   |   |                     | 287     |   |   |   | 24,713 |   |   |   | — |   |   |   | 25,000 |   |
|                                                              |   |                |    |   |                |   |    |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Sale of 507,041 Private Placement Shares                          |   |                | 507,041 |   |                |   | 51      |              |   |   | —     |   |   |                     | — |   |   |   | 5,070,359 |   |   |   | — |   |   |   | 5,070,410 |   |
|                                                              |   |                |    |   |                |   |    |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Forfeiture of Founder Shares                                      |   |                | — |   |                |   | — |              |   |   | (286,990    | )      |   |                     | (28     | ) |   |   | 28 |   |   |   | — |   |   |   | — |   |
|                                                              |   |                |    |   |                |   |    |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Accretion for Class A common stock subject to possible redemption |   |                | — |   |                |   | — |              |   |   | —     |   |   |                     | — |   |   |   | (5,095,100 | ) |   |   | (1,072,923 | ) |   |   | (6,168,023 | ) |
|                                                              |   |                |    |   |                |   |    |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Stock-based compensation                                          |   |                | — |   |                |   | — |              |   |   | —     |   |   |                     | — |   |   |   | 22,500 |   |   |   | — |   |   |   | 22,500 |   |
|                                                              |   |                |    |   |                |   |    |              |   |   |        |   |   |                     |    |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Net loss                                                          |   |                | — |   |                |   | — |              |   |   | —     |   |   |                     | — |   |   |   | — |   |   |   | (264,719 | ) |   |   | (264,719 | ) |
| Balance – December 31, 2020                                 |   |                | 507,041 |   |                | $      | 51      |              |   |   | 2,588,010   |   |   | $                        | 259     |   |   | $ | 22,500 |   |   | $ | (1,337,642 | ) |   | $ | (1,314,832 | ) |

----

Table of Contents

| Cash Flows from Operating Activities:                                         |   |   |         |
|-------------------------------------------------------------------------------|--------|--------|--------------|
| Net loss                                                                      |   | $      | (264,719     | ) |
| Adjustments to reconcile net loss to net cash used in operating activities:   |   |   |         |   |
| Stock-based compensation expense                                              |   |   | 22,500       |   |
| Interest earned on marketable securities held in Trust Account                |   |   | (3,108       | ) |
| Unrealized loss on marketable securities held in Trust Account                |   |   | 981          |   |
| Changes in operating assets and liabilities:                                  |   |   |         |   |
| Prepaid expenses                                                              |   |   | (521,067     | ) |
| Accrued expenses                                                              |   |   | 50,892       |   |
| Net cash used in operating activities                                         |   |   | (714,521     | ) |
|                                                                          |   |   |         |   |
| Cash Flows from Investing Activities:                                         |   |   |         |   |
| Investment of cash in Trust Account                                           |   |   | (103,520,402 | ) |
| Net cash used in investing activities                                         |   |   | (103,520,402 | ) |
|                                                                          |   |   |         |   |
| Cash Flows from Financing Activities:                                         |   |   |         |   |
| Proceeds from issuance of Class B common stock to Sponsor                     |   |   | 25,000       |   |
| Proceeds from sale of Shares, net of underwriting discounts paid              |   |   | 101,449,992  |   |
| Proceeds from sale of Private Placement Shares                                |   |   | 5,070,410    |   |
| Funds due to Sponsor                                                          |   |   | 2,305        |   |
| Proceeds from promissory note – related party                           |   |   | 175,348      |   |
| Repayment of promissory note – related party                            |   |   | (175,000     | ) |
| Payment of offering costs                                                     |   |   | (423,567     | ) |
| Net cash provided by financing activities                                     |   |   | 106,124,488  |   |
|                                                                          |   |   |         |   |
| Net Change in Cash                                                            |   |   | 1,889,565    |   |
| Cash – Beginning of period                                              |   |   | —      |   |
| Cash – End of period                                                    |   | $      | 1,889,565    |   |
|                                                                          |   |   |         |   |
| Non-Cash investing and financing activities:                                  |   |   |         |   |
| Initial classification of Class A common stock subject to possible redemption |   | $      | 103,520,402  |   |
| Deferred underwriting fee payable                                             |   | $      | 3,623,214    |   |
| Offering costs included in accrued offering costs                             |   | $      | 50,832       |   |

----

Table of Contents

----

Table of Contents

----

Table of Contents

| Balance Sheet as of December 31, 2020         |   | As PreviouslyReported |       |   | Adjustment |   |       | As Restated |   |
|-----------------------------------------------|--------|-----------------------|------------|--------|------------|--------|------------|-------------|--------|
| Common stock subject to possible redemption   |   | $                     | 97,205,562 |   |       | $      | 6,314,840  |        |   | $ | 103,520,402 |   |
| Common stock                                  |   | $                     | 114        |   |       | $      | (63        | )           |   | $ | 51 |   |
| Additional paid-in capital                    |   | $                     | 5,264,354  |   |       | $      | (5,241,854 | )           |   | $ | 22,500 |   |
| Accumulated deficit                           |   | $                     | (264,719   | )      |       | $      | (1,072,923 | )           |   | $ | (1,337,642 | ) |
| Total Stockholders’ Equity (Deficit)    |   | $                     | 5,000,008  |   |       | $      | (6,314,840 | )           |   | $ | (1,314,832 | ) |
| Class A Shares Subject to Possible Redemption |   |                  | 9,720,556  |   |       |   | 631,484    |        |   |   | 10,352,040 |   |

| Statement of Operations for the Period from August 27, 2020 (Inception) Through December 31, 2020          |   | As PreviouslyReported |      |   | Adjustment |   |       | As Restated |   |
|------------------------------------------------------------------------------------------------------------|--------|-----------------------|-----------|--------|------------|--------|------------|-------------|--------|
| Basic and diluted weighted average shares outstanding, Class A common stock subject to possible redemption |   |                  | 9,399,759 |   |       |   | (9,399,759 | )           |   |   | — |   |
| Basic and diluted net income per share, Class A common stock subject to possible redemption                |   | $                     | —   |   |       | $      | —    |        |   | $ | — |   |
| Basic and diluted weighted average shares outstanding, Non-redeemable common stock                         |   |                  | 2,949,106 |   |       |   | (2,949,106 | )           |   |   | — |   |
| Basic and diluted net loss (income) per share, Non-redeemable common stock                                 |   | $                     | (0.09     | )      |       | $      | 0.09       |        |   | $ | — |   |
| Weighted average shares outstanding of Class A common stock                                                |   |                  | —   |   |       |   | 3,398,183  |        |   |   | 3,398,183 |   |
| Basic and diluted net loss per share, Class A common stock                                                 |   | $                     | —   |   |       | $      | (0.04      | )           |   | $ | (0.04 | ) |
| Weighted average shares outstanding of Class B common stock                                                |   |                  | —   |   |       |   | 2,684,176  |        |   |   | 2,684,176 |   |
| Basic and diluted loss income per share, Class B common stock                                              |   | $                     | —   |   |       | $      | (0.04      | )           |   | $ | (0.04 | ) |

----

Table of Contents

| Condensed Statement of Changes in Shareholders’ Equity (Deficit) for the Period Ended December 31, 2020 |   | As PreviouslyReported |        |   | Adjustment |   |        | As Restated |   |
|---------------------------------------------------------------------------------------------------------------|--------|-----------------------|-------------|--------|------------|--------|-------------|-------------|--------|
| Sale of 10,352,040 shares, net of underwriter discounts and offering expenses                                 |   | $                     | 97,352,379  |   |       | $      | (97,352,379 | )           |   | $ | — |   |
| Initial value of Class A Common Stock subject to redemption                                                   |   | $                     | (97,205,562 | )      |       | $      | 97,205,562  |        |   | $ | — |   |
| Accretion for Class A Common Stock to redemption amount                                                       |   | $                     | —     |   |       | $      | (6,168,023  | )           |   | $ | (6,168,023 | ) |
| Total Shareholders’ Equity (Deficit)                                                                    |   | $                     | 5,000,008   |   |       | $      | (6,314,840  | )           |   | $ | (1,314,832 | ) |

| Condensed Statement of Cash Flows for the Period from August 27, 2020 (Inception) Through December 31, 2020 |   | As PreviouslyReported |       |   | Adjustment |   |      | As Restated |   |
|-------------------------------------------------------------------------------------------------------------|--------|-----------------------|------------|--------|------------|--------|-----------|-------------|--------|
| Initial classification of Class A common stock subject to possible redemption                               |   | $                     | 97,325,187 |   |       | $      | 6,195,215 |        |   | $ | 103,520,402 |   |
| Change in value of Class A common stock subject to possible redemption                                      |   | $                     | (119,625   | )      |       | $      | 119,625   |        |   | $ | — |   |

----

Table of Contents

| Gross proceeds                                      |   | $      | 103,520,402 |   |
|-----------------------------------------------------|--------|--------|-------------|--------|
| Less:                                               |   |   |        |   |
| Class A common stock issuance costs                 |   | $      | (6,168,023  | )      |
| Plus:                                               |   |   |        |   |
| Accretion of carrying value to redemption value     |   | $      | 6,168,023   |   |
|                                                |   |   |        |   |
| Class A common stock subject to possible redemption |   | $      | 103,520,402 |   |

----

Table of Contents

|                                                  |   | For the Period from August 27,                    2020 (Inception) Through                  December 31, 2020 |      |
|-------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------------|-----------|
|                                                  |   | Class A                                                                                                       |      |   | Class B |   |
| Basic and diluted net loss per common stock           |   |                                                                                                          |      |   |   |   |
| Numerator:                                            |   |                                                                                                          |      |   |   |   |
| Allocation of net loss, as adjusted                   |   | $                                                                                                             | (147,897  | ) |   | $ | (116,822 | ) |
| Denominator:                                          |   |                                                                                                          |      |   |   |   |   |   |
| Basic and diluted weighted average shares outstanding |   |                                                                                                          | 3,398,183 |   |   |   | 2,684,176 |   |
| Basic and diluted net loss per common stock           |   | $                                                                                                             | (0.04     | ) |   | $ | (0.04 | ) |

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

----

Table of Contents

|                                                       |   | Number ofShares |    |
|------------------------------------------------------------|--------|-----------------|---------|
| Unvested Shares Outstanding at August 27, 2020 (inception) |   |            | — |   |
| Granted                                                    |   |            | 248,000 |   |
| Forfeited                                                  |   |            | — |   |
| Vested                                                     |   |            | — |   |
| Unvested Outstanding at December 31, 2020                  |   |            | 248,000 |   |
|                                                |   | December 31,                  2020 |    |
|-----------------------------------------------------|--------|------------------------------------|---------|
| Deferred tax assets (liabilities)                   |   |                               |    |
| Net operating loss carryforward                     |   | $                                  | 51,301  |   |
| Stock compensation                                  |   |                               | 4,725   |   |
| Unrealized gain on marketable securities            |   |                               | (435    | ) |
| Total deferred tax assets (liabilities)             |   |                               | 55,591  |   |
| Valuation Allowance                                 |   |                               | (55,591 | ) |
| Deferred tax assets (liabilities), net of allowance |   | $                                  | — |   |
|                          |   | As of December 31,                  2020 |    |
|-------------------------------|--------|------------------------------------------|---------|
| Federal                       |   |                                     |    |
| Current                       |   | $                                        | — |   |
| Deferred                      |   |                                     | (55,591 | ) |
|                          |   |                                     |    |   |
| State and Local               |   |                                     |    |   |
| Current                       |   |                                     | — |   |
| Deferred                      |   |                                     | — |   |
|                          |   |                                     |    |   |
| Change in valuation allowance |   |                                     | 55,591  |   |
|                          |   |                                     |    |   |
| Income tax provision          |   | $                                        | — |   |

----

Table of Contents

|                                    |   | December 31, 2020 |   |
|-----------------------------------------|--------|-------------------|--------|
|                                    |   |              |   |
| Statutory federal income tax rate       |   |              | 21.0   | % |
| State taxes, net of federal tax benefit |   |              | 0.0    | % |
| Valuation allowance                     |   |              | (21.0  | )% |
| Income tax provision                    |   |              | 0.0    | % |

|  | Level 1: | Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur                    with sufficient frequency and volume to provide pricing information on an ongoing basis. |
|--|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | Level 2: | Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical                    assets or liabilities in markets that are not active. |
|--|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | Level 3: | Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability. |
|--|---------------|--------------------------------------------------------------------------------------------------------------------------------------|

| Description                                 |   | Level  |   |   | December 31,2020 |   |
|---------------------------------------------|--------|--------|--------|--------|------------------|--------|
| Assets:                                     |   |   |   |   |             |   |
| Marketable securities held in Trust Account |   |   | 1      |   |             | $      | 103,522,529 |   |

----